For patients with advanced cSCC who are not amenable to curative-intent treatment with surgery and/or chemo-/radiotherapy, high-affinity PD-1 inhibitors such as cemiplimab or pembrolizumab are emerging as a viable option for first-line treatment. The gene discussed is PDCD1; the disease is skin squamous cell carcinoma.